Navigation Links
Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
Date:11/27/2007

ndidates in clinical development. In addition to iloperidone, Vanda is developing VEC- 162, a compound for the treatment of sleep and mood disorders which is currently in Phase III development for sleep disorders. Vanda's third product candidate in clinical development, VSF-173, is currently in Phase II development for the treatment of excessive sleepiness. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Note Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A)
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  Mail-service and specialty ... consumers, employers and government health plans $11.8 billion ... by the Pharmaceutical Care Management Association (PCMA). ... offers one of the easiest ways to reduce ... Mark Merritt . "Policymakers should resist efforts to ...
(Date:3/4/2015)... UPM Pharmaceuticals, a division of Gregory Pharmaceutical ... to manufacture Flibanserin 100 mg tablets. Sprout has submitted ... drug approved to treat hypoactive sexual desire disorder (HSDD), ... The tablets will be manufactured at UPM,s 475,000 ... . Dr. John M. Gregory , ...
(Date:3/4/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... the licensing, development and commercialization of innovative biopharmaceutical products ... at the Barclays Global Healthcare Conference to ... Beach Hotel in Miami , FL.  ... President and Chief Executive Officer of Aratana Therapeutics, will ...
Breaking Medicine Technology:PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Illinois Employers, Consumers and Public Programs by $11.8 Billion 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 3Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2
... efficacy of ACTEMRA across a broad range of rheumatoid ... NUTLEY, N.J., June 9 One-year data from the ... THE Prevention of Structural Joint Damage) study ... patients treated with ACTEMRA(R) (tocilizumab), a novel interleukin-6 (IL-6) ...
... Findings Published in June Issue of Circulation , ... United Therapeutics Corporation (Nasdaq: UTHR ) and ... today announced the results of a pivotal 16-week study ... well tolerated, improved exercise capacity and improved time to ...
Cached Medicine Technology:Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 2Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 3Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 4Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 5Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 6Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 7Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 8Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 2Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 3Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 4Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 5Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 6
(Date:3/4/2015)... March 04, 2015 With the growing influence ... lives of our teens and young adults, combined with the ... and confusing to try to keep up with what kids ... or trend is replaced on a daily basis. , The ... and the slang that is used to discreetly talk about ...
(Date:3/4/2015)... BC (PRWEB) March 04, 2015 Starting ... perform LASIK and PRK procedures at their new location ... Correction, Dr. Joseph King and Dr. Gabriel Chu also ... practice in Surrey is named Fraser Valley Cataract and ... is accredited by the College of Physicians and Surgeons ...
(Date:3/4/2015)... New York, NY (PRWEB) March 04, 2015 ... within the centerfold of The San Francisco Chronicle with ... readership of 500,000 readers. Its digital component is distributed ... a network of top news sites and partner outlets. ... click here. , Milorganite is composed of ...
(Date:3/4/2015)... 04, 2015 As seen on ... can be a painful condition in which the ... of the uterus leading to very unpleasant symptoms and ... can have a terrible effect on women’s quality of ... the most common cause of infertility in women and ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The popular ... of their new L-Style Revolution™ Program. The customized program ... and women of all health and fitness levels to ... goals faster than traditional methods. , “We’re really proud ... customized plans based on award winning techniques to help ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:King LASIK relocates to Surrey, British Columbia 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2
... gum disease , , WEDNESDAY, Dec. 12 (HealthDay News) ... and a weakened immune response may be to blame, ... In experiments with mice infected with the bacteria ... battle gum infection than their normal-weight counterparts, according to ...
... 12 CG Technology has changed its,name to ... depth,and breadth of services it offers. Carlisle & ... standards of work, while focusing its,business on the ... Consulting Group (CG) is a management consulting,and project-based ...
... System Detects Illegal Payments and Providers, AUSTIN, ... and an NBC News report, U.S. taxpayers are ... to unqualified doctors and health,care providers. A new ... however, can make a significant impact on reducing ...
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer ... today announced that James L. Cox, M.D. has,agreed ... Cox, reputation as a,preeminent authority in the surgical ... serves as the foundation for ATS 3f(R),tissue valve ...
... We are encouraged by the,positive results of the ... D.C., showing promising strides in the right direction,with significant ... of a larger trend for all measured age groups ... past six years (2001-2007)., MTF, now in its ...
... presents $5,000 each to six community organizations in ... underserved areas, ... it will provide a total of $30,000 in end of,year donations to ... given to six agencies in northern and,southern California to assist vulnerable populations., ...
Cached Medicine News:Health News:Obesity Weakens Immune Response 2Health News:Technology can Dramatically Reduce Billions of Dollars in Medicaid, Medicare Fraud 2Health News:ATS Medical Appoints James L. Cox, M.D. as Medical Director 2Health News:ATS Medical Appoints James L. Cox, M.D. as Medical Director 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 4Health News:Blue Cross of California Gives $30,000 in Holiday Donations to Food Banks Throughout the State 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: